Press Release April 8, 2013

InDex Pharmaceuticals reports completion of patient recruitment in Phase III Ulcerative Colitis Study (COLLECT) with Kappaproct®

Stockholm, April 8, 2013 - InDex Pharmaceuticals today announced the completion of patient enrollment for its Phase III COLLECT study of Kappaproct. The multinational, randomized, double-blind, placebo-controlled study reached the recruitment goal of 120 patients with treatment-refractory Ulcerative Colitis (UC). InDex is expecting final study results in mid-2014.

The Phase III trial is designed to assess Kappaproct's efficacy and safety in treatment-refractory UC patients. This cohort consists of chronic active UC patients who have failed all currently available pharmaceutical treatment and whose only remaining treatment option is surgical removal of the colon. This is a rare group of patients with a very high unmet medical need. Kappaproct has an Orphan Drug Designation in Europe.

The study is conducted in seven European countries. The primary endpoint of the study is the induction of clinical remission at week 12. Secondary endpoints, among others, are the rate of and time to colectomy. The patients will be followed for a total of 52 weeks.

"This is a significant achievement for InDex Pharmaceuticals and we thank everyone involved in the study," says Jesper Wiklund, CEO of InDex Pharmaceuticals. "It was encouraging to observe an exponential increase in the recruitment rate in the study so that we completed patient recruitment in less than one year. Considering the fact that this is a small patient population, the fast recruitment rate is a sign of enthusiasm for the study among investigators, patients and other stakeholders in the medical community. This enthusiasm bodes well for the future as we evaluate the optimal way to bring Kappaproct to approval and to market. If the encouraging results from the previous studies are confirmed in COLLECT, we trust that Kappaproct can become an effective new treatment for patients with treatment-refractory UC."

Kappaproct is a DNA-based immunomodulatory sequence (DIMS) targeting the toll-like receptor 9 (TLR9). Kappaproct has shown positive effects on key symptoms of UC such as stool frequency, blood in stool and mucosal healing in a previous phase II proof-of-concept study. Kappaproct has also demonstrated a favorable safety and side effect profile in previous clinical trials.

About InDex Pharmaceuticals
InDex Pharmaceuticals is a biopharmaceutical company focusing on the discovery and development of immunology-based treatments, exclusively addressing disease states with a high unmet medical need. The company was founded in 2000 and is located in Stockholm, Sweden.

For additional information about COLLECT, Kappaproct and InDex Pharmaceuticals, please visit www.indexpharma.com and http://clinicaltrials.gov/ct2/show/NCT01493960.

Contact InDex Pharmaceuticals:
Jesper Wiklund, CEO
Tel: +46 8 508 847 35/ +46 (0)733 59 05 53
jesper.wiklund@indexpharma.com

Media Inquiries:
akampion
Dr. Ludger Wess or Ines-Regina Buth
Tel.: +49 (0)40 88 16 59 64 / +49 (0)30 2363 2768
info@akampion.com